FDA Expands CRISPR Casgevy Approval to Children Age 2 with Sickle Cell Disease
Tags Health Tech · AI
FDA expanded approval of Vertex/CRISPR Therapeutics' Casgevy gene therapy to children as young as 2 with sickle cell disease, up from previous minimum age of 12. The CRISPR/Cas9-based therapy now makes approximately 5,500 additional U.S. children eligible. Clinical trial data showed 8 of 11 sickle cell patients (ages 5-11) achieved no severe pain crises for 12+ months, while 8 of 9 beta thalassemia patients achieved transfusion independence.
Technical significance
Expanded pediatric approval demonstrates CRISPR safety in younger patients and accelerates gene therapy adoption. Clinical data showing sustained efficacy in children validates platform for early intervention. FDA's extrapolation from 5-11 data to age 2 indicates regulatory confidence in mechanism-based approvals, potentially streamlining future gene therapy authorizations.